TABLE 3.
Prevalence of baseline polymorphisms in GT1b-infected patients
| Target and variant | %a |
|---|---|
| NS3 (nb = 119), nonec | |
| NS5A (n = 130) | |
| R30Q | 8.5 |
| L31I | 2.3 |
| L31M | 6.2 |
| P58A | 0.8 |
| P58L | 0.8 |
| P58R | 0.8 |
| P58S | 3.8 |
| P58T | 2.4 |
| Y93H | 5.4 |
| NS5B (n = 125) | |
| C316H | 0.8 |
| C316K | 0.8 |
| C316N | 18.4 |
| C316W | 0.8 |
| S368A | 0.8 |
| M414L | 0.8 |
| C445F | 1.6 |
| S556G | 16.0 |
a
Percentage of patients with the baseline polymorphism relative to the GT1b strain Con1 reference sequence.
b
n, number of samples sequenced for that target.
c
None, baseline polymorphisms were not detected at resistance-associated amino acid positions.